Zhejiang Kanglaite Group

Zhejiang Kanglaite Group is a prominent Chinese pharmaceutical company focused on the modernization of Traditional Chinese Medicine (TCM) for oncology. The company's core product, Kanglaite Injection, is a patented botanical lipid emulsion derived from Coix seed (Job's tears) and is widely utilized in China as an adjunctive or primary therapy for various malignancies. Notably, Kanglaite was the first TCM-based intravenous injection to receive IND approval from the U.S. FDA, progressing into Phase 2 and Phase 3 clinical trials in the United States. The group maintains a strong focus on research and development, aiming to bridge the gap between traditional herbal therapies and evidence-based Western medicine. Founded by Academician Li Dapeng, the group operates large-scale GMP manufacturing facilities for botanical extraction and emulsion production.